Haemonetics (HAE) said its second-quarter net income rose to $18.05 million or $0.69 per share from $14.81 million or $0.57 per share in the comparable period. Non-GAAP net income for the latest quarter grew to $18.05 million or $0.69 per share from $15.01 million or $0.58 per share last year. On average, 8 analysts polled by Thomson Reuters expected earnings per share of $0.65 for the quarter. Analysts' estimate typically excludes one-time items.
Net revenues for the second quarter increased 7.6% to $157.07 million from $145.92 million last year. Six analysts estimated revenues of $157.84 million. Haemonetics expects full-year Platelet revenue growth in a range of 0-2%. The company confirmed its full-year guidance of 8-11% revenue growth and earnings per share in a range of $2.75 - $2.85. Eight analysts expect earnings per share of $2.81 for the full year.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.